Reference

1. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. *Lancet* 2016; 388(10049): 1081-8.
2. *Global hepatitis report, 2017*. Geneva: World Health Organization; 2017 (http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/, accessed 21 October 2019).
3. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. *Clin Infect Dis* 1995; 20(4): 992-1000.
4. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. *J Viral Hepat* 2004; 11(2): 97-107.
5. *Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection*. Geneva: World Health Organization; 2018 (https://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2018/en/ , accessed 22 October 2019).
6. Westbrook RH, Dusheiko G. Natural history of hepatitis C. *J Hepatol* 2014; 61(1 Suppl):S58–68.
7. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. *Lancet* 2011; 378(9791): 571-83.
8. McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. *J Infect Dis* 1985; 151(4): 599-603.
9. Marcellin P. Hepatitis C: the clinical spectrum of the disease. *J Hepatol* 1999; 31 Suppl 1: 9-16.
10. Aisyah DN, Shallcross L, Hully AJ, et al. Assessing hepatitis C spontaneous clearance and understanding associated factors-A systematic review and meta-analysis. *J Viral Hepat* 2018; 25(6): 680-98.
11. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *J Hepatol* 2006; 45(4): 529-38.
12. Huang YT, Jen CL, Yang HI, et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J *Clin Oncol* 2011; 29(27): 3643-50.
13. World Health Organization. Hepatitis B vaccines: WHO position paper – July 2017. *Wkly Epidemiol* Rec 2017; 92(27): 369-92.
14. *Guidelines for the screening care and treatment of persons with chronic hepatitis C infection*. Updated version, April 2016. Geneva: World Health Organization; 2016 (https://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016/en/ , accessed 27 April 2020).
15. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. *Ann Intern Med* 2017;166(9): 637-48.
16. *Regional Action Plan for Viral Hepatitis in the Western Pacific 2016-2020*. Geneva: World Health Organization; 2016 (https://iris.wpro.who.int/handle/10665.1/13141 , accessed 30 January 2020).
17. *Global health sector strategy on viral hepatitis 2016-2021*. Geneva: World Health Organization; 2016 (https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/ , accessed 18 October 2019).
18. Hong Kong achieves goal of hepatitis B control verified by the World Health Organization Western Pacific Region. Department of Health, Hong Kong; *Communicable Diseases Watch* 2011;8(15).

19. *Surveillance of Viral Hepatitis in Hong Kong – 2018 Report*. Hong Kong: Department of Health, 2019 (https://www.hepatitis.gov.hk/tc_chi/document_cabinet/files/hepsurv18.pdf , accessed 20 April 2020).
20. Liu KS, Seto WK, Lau EH, et al. A Territorywide Prevalence Study on Blood-Borne and Enteric Viral Hepatitis in Hong Kong. *J Infect Dis* 2019; 219(12): 1924-33.
21. Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. *Lancet Gastroenterol Hepatol* 2018; 3(6): 383-403.
22. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. *Lancet Gastroenterol Hepatol* 2017; 2(3): 161-76.
23. Chan GC, Lim W, Yeoh EK. Prevalence of hepatitis C infection in Hong Kong. *J Gastroenterol Hepatol* 1992; 7(2): 117-20.
24. Chan TM, Lok AS, Cheng IK, et al. Prevalence of hepatitis C virus infection in hemodialysis patients: a longitudinal study comparing the results of RNA and antibody assays. *Hepatology* 1993; 17(1): 5-8.
25. Lee KC, Lim WW, Lee SS. High prevalence of HCV in a cohort of injectors on methadone substitution treatment. *J Clin Virol* 2008; 41(4): 297-300.
26. Wong NS, Chan PC, Lee SS, et al. A multilevel approach for assessing the variability of hepatitis C prevalence in injection drug users by their gathering places. *Int J Infect Dis* 2013; 17(3): e193-8.
27. Chan DP, Lee KC, Lee SS, et al. Community-based molecular epidemiology study of hepatitis C virus infection in injection drug users. *Hong Kong Med J* 2017; 23 Suppl 5(4): 27-30.
28. Wong GL, Chan HL, Loo CK, et al. Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy. *J Gastroenterol Hepatol* 2019; 34(9): 1641-47.
29. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; 68(6):394-424.
30. Yuen MF, Hou JL, Chutaputti A, et al. Hepatocellular carcinoma in the Asia Pacific Region. J *Gastroenterol Hepatol* 2009; 24(3): 346-53.
31. Hong Kong Cancer Registry, Hospital Authority. (https://www3.ha.org.hk/cancereg/ , accessed 1 June 2020)
32. Hutin Y, Nasrullah M, Easterbrook P, et al. Access to Treatment for Hepatitis B Virus Infection - Worldwide, 2016. *MMWR Morb Mortal Wkly Rep* 2018; 67(28): 773-7.
33. Chan HL, Chen CJ, Omede O, et al. The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4. *J Viral Hepat*. 2017; 24 Suppl 2: 25-43.
34. Hui YT, Wong GL, Fung JY, et al. Territory wide population based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong. *Liver Int* 2018; 38(11): 1911-9.
35. Prevention and Control of Viral Hepatitis Infection: *Framework for Global Action*. Geneva: World Health Organization; 2012 (http://www.who.int/hepatitis/publications/Framework/en/ , accessed 30 January 2020).
36. Leung CM, Wong WH, Chan KH, et al. Public awareness of hepatitis B infection: a population-based telephone survey in Hong Kong. *Hong Kong Med J* 2010; 16: 463-9.

37. Yan KK, Wong GL, Wong VW, et al. Rate and factors affecting treatment uptake of patients with chronic hepatitis C in a tertiary referral hospital. *Dig Dis Sci* 2010; 55: 3541-7

38. Fox RD, Bennett NL. Learning and change: implications for continuing medical education. *BMJ* 1998; 316(7129): 466-8.

39. *WHO Technical Considerations and Case Definitions to Improve Surveillance for Viral Hepatitis*. Geneva: World Health Organization; 2016. (https://www.who.int/hepatitis/publications/hep-surveillance-guide-pub/en/, accessed 22 January 2020)

40. *Guidelines for viral hepatitis surveillance and case management*. Atlanta, GA: Centers for Disease Control and Prevention; 2005 (https://www.cdc.gov/hepatitis/PDFs/2005Guidlines-Surv-CaseMngmt.pdf, accessed 15 January 2020).

41. Cheung KW, Seto MT, Kan AS, et al. Immunoprophylaxis failure of infants born to hepatitis B carrier mothers following routine vaccination. *Clin Gastroenterol Hepatol* 2018; 16: 144-5.

42. Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. *N Engl J Med* 2016; 374: 2324-34.

43. Brown RS, McMahon BY, Lok ASF, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis. *Hepatology* 2016;63:319-33.

44. *Regional Framework for the Triple Elimination of Mother-to-Child Transmission of HIV, Hepatitis B and Syphilis in Asia and the Pacific 2018-2030*. Manila: WHO Regional Office for the Western Pacific; 2018 (https://iris.wpro.who.int/handle/10665.1/14193 , accessed 30 January 2020).

45. US CDC. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. *MMWR Recomm Rep* 2018; 67(1); 1-31.

46. European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. *J Hepatol* 2017; 67(2): 370-98.

47. Zuckerman JN. Protective Efficacy, Immunotherapeutic Potential, and Safety of Hepatitis B Vaccines. *J Med Virol* 2006; 78(2): 169-77.

48. *Hepatitis B control through immunization: a reference guide*. Manila: WHO Regional Office for the Western Pacific. (https://iris.wpro.who.int/handle/10665.1/10820 , accessed 30 January 2020)

49. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. *MMWR Recomm Rep* 2005; 54(No. RR-16).

50. Preventing hepatitis B transmission in health care settings – recommended guidelines. Hong Kong: Scientific Working Group on Viral Hepatitis Prevention, Department of Health; 1995. (https://www.hepatitis.gov.hk/english/document_cabinet/files/hepbguidelines.pdf, accessed on 18 June, 2020)

51. Infection control corner, Centre for Health Protection, Department of Health. (https://www.chp.gov.hk/en/resources/346/index.html, accessed on 18 June 2020)

52. Prevention of sharps injury and mucocutaneous exposure to blood and body fluids in healthcare settings. Hong Kong: Centre for Health Protection, Department of Health; 2009. (https://www.chp.gov.hk/files/pdf/prevention_of_sharps_injury_and_mucocutaneous_exposure_to_blood_and_body_fluids.pdf, accessed 18 June 2020)

53. Recommendations on the management and postexposure prophylaxis of needlestick injury or mucosal contact to HBV, HCV and HIV. Hong Kong; Department of Health; 2014. (https://www.chp.gov.hk/files/pdf/recommendations_on_postexposure_management_and_prophylaxis_of_needlestick_injury_or_mucosal_contact_to_hbv_hcv_and_hiv_en_r.pdf, accessed on 18 June 2020)

54. Recommendations on prevention of healthcare-associated transmission of bloodborne viruses during blood sampling. Hong Kong; Department of Health; 2018. (https://www.chp.gov.hk/files/pdf/recommendations_on_prevention_of_healthcare-associated_transmission_of_bloodborne_viruses_during_blood_sampling.pdf, accessed on 18 June 2020)

55. Falade-Nwulia O, Sulkowski MS, Merkow A, et al. Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era. *J Viral Hepat* 2018; 25(3): 220-7.

56. *Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection*. Geneva: World Health Organization; 2015 (https://www.who.int/hepatitis/publications/hepatitis-b-guidelines/en/ , accessed 3 July2020).

57. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. *Clin Infect Dis* 2011; 52(7): 889-900.

58. Everson GT, Balart L, Lee SS, et al. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. *Aliment Pharmacol Ther* 2008; 27(7): 542-51.

59. Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. *Ann Intern Med* 2008; 149(6): 399-403.

60. Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. *Gastroenterology* 2008; 135(3): 821-9.

61. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. *JAMA* 2012; 308(24): 2584-93.

62. Harris RJ, Martin NK, Rand E, et al. New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England. *J Viral Hepat* 2016; 23(8): 631-43.

63. Martin NK, Thornton A, Hickman M, et al. Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights. *Clin Infect Dis* 2016; 62(9): 1072-80.

64. Lazarus JV, Wiktor S, Colombo M et al. Micro-elimination – a path to global elimination of hepatitis C. *Journal of Hepatology* 2017; 67(4): 655-66.

65. Kracht PAM, Arends JE, van Erpecum KJ, et al. Strategies for achieving viral hepatitis C micro-elimination in the Netherlands. *Hepatol Med* Policy 2018; 3: 12.

66. Kwon E, Cho JH, Jang HM, et al. Differential effect of viral hepatitis infection on mortality among Korean maintenance dialysis patients: a prospective multicenter cohort study. *PLoS One* 2015; 10(8): e0135476

67. Kim SM, Song IH. Hepatitis C virus infection in chronic kidney disease: paradigm shift in management. Korean *J Intern Med* 2018; 33(4): 670-8.

68. Michel J, Marina C.B., Wahid D. et at. Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management. *Kidney Int* 2018; 94: 663-73.

69. Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. *Kidney Int* 1997; 51: 981–99.

70. Bhamidimarri KR, Martin P. Finally, Safe and Effective Treatment Options for Hepatitis C in Hemodialysis Patients. *J Hepatol* 2016; 65(1): 7-10.

71. UNAIDS data 2019. Geneva: Joint United Nations Programme on HIV/AIDS; 2019 (https://www.unaids.org/sites/default/files/media_asset/2019-UNAIDS-data_en.pdf, accessed 7 January 2020).

72. Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. *Lancet Infect Dis* 2016; 16(7): 797-808.

73. Lin W, Weinberg EM, Chung RT. Pathogenesis of Accelerated Fibrosis in HIV/HCV Co-Infection. *J Infect Dis* 2013; 207 (Suppl 1): S13-8.

74. Sikavi C, Chen PH, Lee AD, et al. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population. *Hepatology* 2018; 67(3): 847-57.

75. Grebely J, Larney S, Peacock A, et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. *Addiction* 2019; 114(1): 150–66.

76. Schillie S, Wester C, Osborne M, et al. CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020. *MMWR Recomm Rep* 2020; 69(2):1-17.

77. Coffin PO, Rowe C, Santos GM. Novel interventions to prevent HIV and HCV among persons who inject drugs. *Curr HIV/AIDS Rep* 2015; 12: 145–63.

78. Martin NK, Hickman M, Hutchinson SJ, et al. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. *Clin Infect Dis* 2013; 57(Suppl 2): S39-S45.

79. Hellard M, Doyle JS, Sacks-Davis R, et al. Eradication of hepatitis C infection: the importance of targeting people who inject drugs. *Hepatology* 2014; 59(2): 366-69.

80. Scott N, Doyle JS, Wilson DP, et al. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. *Int J Drug Policy* 2017; 47: 107-16.

81. Pitcher AB, Borquez A, Skaathun B, et al. Mathematical modeling of hepatitis C virus (HCV) prevention among people who inject drugs: a review of the literature and insights for elimination strategies. *J Theor Biol* 2019; 481: 194-201.

82. Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. *Clin Infect Dis* 2013;57 (Suppl 2): S56-61.

83. The Estimates (Volume I - General Revenue Account), The 2020-21 Budget. Head 37 – Department of Health [Internet]. The Government of the Hong Kong Special Administrative Region; 2020 [cited 21 April 2020]. Available from: https://www.budget.gov.hk/2020/eng/pdf/head037.pdf

84. Dolan K, Teutsch S, Scheuer N, et al. Incidence and risk for acute hepatitis C infection during imprisonment in Australia. *Eur J Epidemiol* 2010; 25: 143–8.

85. Larney S, Kopinski H, Beckwith CG, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. *Hepatology* 2013; 58: 1215–24.

86. Post JJ, Arain A, Lloyd AR. Enhancing assessment and treatment of hepatitis C in the custodial setting. *Clin Infect Dis* 2013; 57: S70–4.

87. Aspinall EJ, Mitchell W, Schofield J, et al. A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy. *J Viral Hepat* 2016; 23: 1009–16.

88. Maru DS, Bruce RD, Basu S, et al. Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. *Clin Infect Dis* 2008; 47: 952–61.

89. Immunisation coverage of vaccines under the Hong Kong Childhood Immunisation Programme - findings of the 2018 Immunisation Survey on Preschool Children. Department of Health, Hong Kong; *Communicable Diseases Watch* 2019; 16(13): 62-4.

90. Immunisation coverage for children aged two to five: findings of the 2015 immunisation survey. Department of Health, Hong Kong; *Communicable Diseases Watch* 2017; 14(6): 23-6.